On October 30th, GlaxoSmithKline (GSK.US) fell more than 3.8%, closing at $36.7. On the news front, GlaxoSmithKline's revenue in the third quarter was £8.012 billion, a 2% year-on-year decrease, lower than the analyst's expected £8.1 billion; the earnings per share after deducting some items was 49.7 pence, higher than the analyst's forecast of 44 pence. Vaccine sales in the period decreased by 18% to £2.65 billion. (Glory)
美股异动｜葛兰素史克跌超3.8% Q3营收同比下降2%逊预期
U.S. stock market anomaly | glaxosmithkline fell more than 3.8% Q3 revenue year-on-year decline of 2% lower than expected
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated